Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$61.81

6.97 (12.71%)

, P

Pandora

$5.59

-1.82 (-24.56%)

07:35
11/06/17
11/06
07:35
11/06/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Qualcomm (QCOM), Pandora (P), Tenet (THC), First Data (FDC), Apollo Global (APO), Party City (PRTY), and Global Blood Therapeutics (GBT).

QCOM

Qualcomm

$61.81

6.97 (12.71%)

P

Pandora

$5.59

-1.82 (-24.56%)

THC

Tenet

$13.08

-0.76 (-5.49%)

FDC

First Data

$17.13

0.07 (0.41%)

APO

Apollo Global

$31.29

0.65 (2.12%)

PRTY

Party City

GBT

Global Blood Therapeutics

$41.55

2.45 (6.27%)

  • 07

    Nov

  • 09

    Nov

  • 09

    Dec

  • 11

    Dec

QCOM Qualcomm
$61.81

6.97 (12.71%)

10/31/17
DBAB
10/31/17
NO CHANGE
Target $56
DBAB
Hold
Deutsche views Apple report as likely legal posturing
Deutsche Bank analyst Ross Seymore believes the Wall Street Journal's report of Apple (AAPL) designing iPads and IPhones without Qualcomm (QCOM) modems as likely legal posturing. Shares of Qualcomm are down 7% to $50.74 in morning trading. The article does, however, once again highlight that the legal battle between the two companies is escalating and unlikely to end anytime soon, Seymore told investors earlier in a research note. The analyst continues to view Qualcomm as a range-bound stock and keeps a Hold rating on the name.
11/06/17
KEYB
11/06/17
NO CHANGE
KEYB
Broadcom bid for Qualcomm would be impressive 'masterpiece,' says KeyBanc
KeyBanc analyst John Vinh notes that the Wall Street Journal reported that Broadcom (AVGO) is contemplating an unsolicited bid to acquire Qualcomm (QCOM) for $70/share. The analyst believes this deal would make sense, as he sees significant cost synergies and the opportunity for Broadcom to leverage its healthy relationship with Apple (AAPL) to mend the current strife between Qualcomm and Apple. Additionally, Vinh thinks this deal would be meaningfully accretive to Broadcom and could drive consolidated EPS of $22.97, which would imply fair value of $350.In his M&A scenario analysis, the analyst is assuming Qualcomm backs out of its bid for NXP Semiconductors (NXPI) and Broadcom looks to divest QTL and closes on its acquisition of Brocade (BRCD). In terms of implications, he views as Positive for Cavium's (CAVM) ThunderX business.
11/06/17
NOMU
11/06/17
NO CHANGE
Target $300
NOMU
Buy
Broadcom price target raised to $300 from $275 at Nomura Instinet
Nomura Instinet analyst Romit Shah raised his price target for Broadcom Limited (AVGO) to $300 following reports that the company is lining up for a bid for Qualcomm (QCOM). Broadcom's proposed acquisition of Qualcomm at $75 per share could drive earnings to roughly $25 per share in 2019 and $27-$28 per share in 2020, Shah tells investors in a research note titled "San Diego's Biggest Enchilada." The analyst believes Broadcom would encourage Qualcomm to complete the acquisition of NXP Semiconductors (NXPI). Further, he thinks Broadcom could potentially spin out Qualcomm's royalty business in order to fund the transaction and gain regulatory approval. Shah keeps a Buy rating on Broadcom.
11/06/17
JEFF
11/06/17
NO CHANGE
Target $315
JEFF
Buy
Broadcom price target raised to $315 from $286 at Jefferies
Jefferies analyst Mark Lipacis raised his price target for Broadcom Limited (AVGO) to $315 following reports that the company is planning a $70 per share unconsolidated bid for Qualcomm (QCOM). The analyst's sensitivity analysis indicates 38%-42% earnings accretion at a five-times net leverage ratio for both and 18%-19% earnings accretion at a three times leverage for NXP Semiconductors (NXPI). Lipacis keeps a Buy rating on Broadcom shares.
P Pandora
$5.59

-1.82 (-24.56%)

11/03/17
11/03/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Blue Apron (APRN) downgraded to Underweight from Equal Weight at Barclays with analyst Ross Sandler saying while the company's third quarter revenue topped his estimate by 10%, the company burned $78M in free cash flow in the quarter, more than he expected. 2. Teva (TEVA) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying following the "disappointing" third quarter results and fourth quarter outlook, the analyst does not see enough to justify a Buy rating given the "multitude of uncertainties" on Teva's capital structure, core generic business, and management's ability to forecast its business. 3. Pandora (P) downgraded to Neutral from Buy at B. Riley FBR, to Neutral from Overweight at JPMorgan, and to Hold from Buy at SunTrust and Stifel. 4. Flowserve (FLS) downgraded to Neutral from Buy at Seaport Global and to Market Perform from Outperform at BMO Capital. 5. Newell Brands (NWL) downgraded to Outperform from Top Pick at RBC Capital and to Market Perform from Strong Buy at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/17
ADAM
11/03/17
NO CHANGE
Target $11
ADAM
Buy
Pandora price target lowered to $11 from $14 at Canaccord
Canaccord analyst Michael Graham lowered his price target on Pandora to $11 from $14 citing what he said is a transition quarter. The analyst noted the ad-listener base declined and advertising missed revenue consensus, but management outlined a few areas of investment that would get those numbers moving in the right direction. Graham maintained his Buy rating on Pandora shares.
11/03/17
RILY
11/03/17
DOWNGRADE
Target $8
RILY
Neutral
Pandora downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR downgraded Pandora Media to Neutral with an $8 price target following the company's Q3 results. The firm notes that advertising revenues are expected to decline in Q4. This is the fourth downgrade of Pandora today.
11/03/17
JPMS
11/03/17
DOWNGRADE
Target $9
JPMS
Neutral
Pandora downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Doug Anmuth downgraded Pandora Media to Neutral and cut his price target for the shares to $9 from $14. Advertising trends are deteriorating and it will take time for the company to realize the benefits of its advertising technology investments, Anmuth tells investors in a research note. He does not see a near-term catalyst for the shares.
THC Tenet
$13.08

-0.76 (-5.49%)

09/14/17
KEYB
09/14/17
NO CHANGE
KEYB
Tenet unlikely to find buyer for whole company, says KeyBanc
KeyBanc analyst Jason Gurda notes that Bloomberg is reporting that Tenet has hired advisers to explore strategic alternatives, including a potential sale. The analyst believes it is unlikely it will find a buyer for the whole company due to its high level of debt and the likely lack of interest from potential strategic buyers. However, Gurda does believe that Tenet could expand its effort to divest individual hospitals and/or its Conifer subsidiary at multiples that would be accretive to where the shares are currently trading and would accelerate de-leveraging. But it is not clear at the moment how far management is willing to go in breaking up the business, he adds.
09/14/17
RHCO
09/14/17
NO CHANGE
RHCO
'Potential public suitors' for Tenet 'limited,' says SunTrust
SunTrust analyst David MacDonald says that "potential public suitors" for Tenet are "limited," while its free cash flow "remains sluggish." However, the analyst says that the company's assets are "intriguing," as its non-hospital assets are being undervalued by the market. He keeps a $16 price target and a Hold rating on the shares.
11/03/17
FBCO
11/03/17
INITIATION
Target $15
FBCO
Neutral
Tenet initiated with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice started Tenet Healthcare with a Neutral rating and $15 price target.
09/14/17
RBCM
09/14/17
NO CHANGE
RBCM
Tenet unlikely to be acquired, says RBC Capital
After The Wall Street Journal reported that Tenet (THC) hired advisors to purse strategic options, RBC Capital analyst Frank Morgan says that all of Tenet probably won't be acquired, given its "significant" debt levels. He says that the company's ambulatory unit is the most likely part of the company to be sold or spun off. The analyst says that HCA (HCA) could be "interested" in some of Tenet's markets, but he does not believe that it wants to buy all of Tenet's hospitals. The analyst does not expect any deals made by Tenet to cause its share price to increase unless it manages to sell its hospitals for rates above their current market value. Morgan keeps a Sector Perform rating on the stock.
FDC First Data
$17.13

0.07 (0.41%)

10/20/17
WEDB
10/20/17
UPGRADE
WEDB
Outperform
First Data upgraded to Outperform from Neutral at Wedbush
10/27/17
CHLM
10/27/17
NO CHANGE
Target $25
CHLM
Buy
Craig-Hallum says its time to buy First Data
Craig-Hallum analyst Brad Berning said First Data's recent acquisitions of CardConnect and Blue Pay demonstrate management's strategic move to return to growth and will position the company to be a player in the ISV channel, where they historically have been nonexistent. Based on management commentary about achieving 4x leverage by 2019 after $1.5B in acquisitions, Berning sees approximately $500M in upside to is 2019 adjusted EBTIDA estimate of $3.58B. The analyst sees growth and margins accelerating and told investors "its time to buy First Data" and said there could be upside to his $25 price target. Berning rates First Data a Buy.
10/02/17
BUCK
10/02/17
INITIATION
Target $23
BUCK
Buy
First Data initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler initiated First Data with a Buy and $23 price target. The analyst sees numerous tailwinds including improving free cash flow generation which will accelerate deleveraging, and a rebound in joint-ventures, acquisitions, and foreign exchange.
10/20/17
10/20/17
UPGRADE
Target $25

Outperform
Follow-up: First Data upgraded to Outperform on aggressive M&A at Wedbush
As previously reported, Wedbush upgraded First Data to Oupterform from Neutral and increased the price target to $25 from $20. Analyst Moshe Katri said the recent CardConnect and BluePay acquisitions boost First Data's North American Global Business Services segments and will help accelerate top line growth. Further, the analyst believes the acquisitions, when combined with First Data's improving margin and free cash flow profiles, will drive the multiple higher.
APO Apollo Global
$31.29

0.65 (2.12%)

11/02/17
WELS
11/02/17
NO CHANGE
Target $39
WELS
Outperform
Apollo Global price target raised to $39 from $34 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for Apollo Global to $39 from $34 after its Q3 results were well above expectations. The analyst reiterates an Outperform rating on the shares.
09/19/17
WELS
09/19/17
NO CHANGE
WELS
Wells Fargo dropping coverage of ClubCorp after acquisition
Wells Fargo is dropping coverage of ClubCorp (MYCC) after it was acquired by an affiliate of certain investment funds managed by Apollo Global Management (APO).
06/08/17
BOFA
06/08/17
UPGRADE
BOFA
Buy
Carlyle Group upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Carlyle Group (CG) to Buy saying the outlook for alternative asset managers is improving following a challenging 2015 and 2016. The analyst highlights "healthy" fundraising, improving returns, and rising distributions for the space. Carrier raised his price target for Carlyle to $21 from $20 while noting that Apollo Global (APO) remains his top pick in the space.
02/09/17
WELS
02/09/17
NO CHANGE
WELS
Apollo Global stock could rise 15% on Athene Holding deal, says Wells Fargo
Wells Fargo estimates that Apollo Global's (APO) EPS could be boosted by 40c and its stock could rise 10%-15% if Athene Holding (ATH) buys Fidelity & Guarantee Life. The firm notes that Apollo Global "recognizes revenue and earnings (positive or negative) tied to Athene Holding stock price movements." Wells keeps an Outperform rating on Apollo Global.
PRTY Party City

10/24/17
10/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Hasbro (HAS) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she believes the 8.6% selloff in shares yesterday on news of the Toys R Us bankruptcy is overdone. 2. Party City (PRTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Wayne Hood saying the 34% pullback in shares over the past 12 months creates a favorable risk/reward entry point. 3. Alon USA Partners (ALDW) upgraded to Outperform from Neutral at Macquarie. 4. EnLink Midstream (ENLC) upgraded to Buy from Neutral at UBS with analyst Shneur Gershuni saying the company's 16% interest in Oklahoma Tall Oak is underappreciated following the recent selloff in the shares. 5. Delek US (DK) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
BMOC
10/24/17
UPGRADE
Target $16
BMOC
Outperform
Party City upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Wayne Hood upgraded Party City to Outperform saying the 34% pullback in shares over the past 12 months creates a favorable risk/reward entry point. Channel checks do not suggest comp-store sales below expectations nor unplanned promotions that would indicate broad weakness, Hood tells investors in a research note. The analyst has a $16 price target for the shares.
GBT Global Blood Therapeutics
$41.55

2.45 (6.27%)

08/03/17
OPCO
08/03/17
INITIATION
Target $53
OPCO
Outperform
Global Blood Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Global Blood Therapeutics with an Outperform and a $53 price target telling investors it is conducting a pivotal trial of GBT440 that has the potential to demonstrate clinical benefits reaching well beyond reduction in vaso-occlusive events in patients with sickle cell disease. With multiple readouts, the analyst believes the company may represent an attractive takeout for a large biopharmaceutical company seeking to expand its footprint in hematologic and/or pulmonary indications.
05/01/17
JANY
05/01/17
INITIATION
Target $37
JANY
Buy
Global Blood Therapeutics initiated with a Buy at Janney Capital
Janney Capital initiated Global Blood Therapeutics with a Buy and a $37 price target.
09/20/17
NEED
09/20/17
INITIATION
Target $51
NEED
Buy
Global Blood Therapeutics initiated with a Buy at Needham
Needham analyst Danielle Brill initiated Global Blood Therapeutics with a Buy and a $51 price target.
10/30/17
MSCO
10/30/17
NO CHANGE
MSCO
Overweight
Global Blood case studies positive, but just anecdotal, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the case studies presented recently by Global Blood Therapeutics are "directionally positive," but he is cautious about reading too much into the cases as they are just anecdotal examples of two patients. Harrison has an Overweight rating and $56 price target on Global Blood Therapeutics shares.

TODAY'S FREE FLY STORIES

EADSY

Airbus

$26.16

0.62 (2.43%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Periodicals
Airbus COO expected to step down, Reuters reports »

Airbus COO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBL

Jabil Circuit

$27.56

-0.99 (-3.47%)

15:34
12/14/17
12/14
15:34
12/14/17
15:34
Options
Jabil Circuit options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 09

    Jan

MCD

McDonald's

$173.34

-0.21 (-0.12%)

, QSR

Restaurant Brands

$61.42

0.09 (0.15%)

15:32
12/14/17
12/14
15:32
12/14/17
15:32
Hot Stocks
Jim Chanos says not short McDonald's, but is short other fast food stocks »

Chanos, in making…

MCD

McDonald's

$173.34

-0.21 (-0.12%)

QSR

Restaurant Brands

$61.42

0.09 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$10.30

-0.66 (-6.02%)

15:30
12/14/17
12/14
15:30
12/14/17
15:30
Options
Express calls active as shares see relative weakness »

Express calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

, DIS

Disney

$111.17

3.555 (3.30%)

15:29
12/14/17
12/14
15:29
12/14/17
15:29
Recommendations
21st Century Fox, Disney analyst commentary  »

21st Century Fox should…

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

DIS

Disney

$111.17

3.555 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

TSLA

Tesla

$339.03

-2 (-0.59%)

15:28
12/14/17
12/14
15:28
12/14/17
15:28
Hot Stocks
Tesla 'already behind' on vehicle autonomy, Chanos says »

Jim Chanos of Kynikos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$339.03

-2 (-0.59%)

15:27
12/14/17
12/14
15:27
12/14/17
15:27
Hot Stocks
Chanos says Tesla CEO Musk 'has broad interpretation of truth' »

Jim Chanos, who is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

BTC

Bitcoin

, BITCOIN

Bitcoin

15:19
12/14/17
12/14
15:19
12/14/17
15:19
General news
Chanos says 'not short' bitcoin but 'speculation' in it indicative of market »

Jim Chanos of Kynikos…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$176.83

4.29 (2.49%)

15:19
12/14/17
12/14
15:19
12/14/17
15:19
Options
Adobe options imply 6.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

EADSY

Airbus

$26.16

0.62 (2.43%)

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Periodicals
Breaking Periodicals news story on Airbus »

Airbus CEO intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
12/14/17
12/14
15:17
12/14/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

, ESRX

Express Scripts

$68.57

0.01 (0.01%)

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Periodicals
Chanos says tax bill will affect healthcare more than people think »

Chanos mentioned…

MNK

Mallinckrodt

$23.11

-0.75 (-3.14%)

ESRX

Express Scripts

$68.57

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

$NYE

NYSE Market Internals

15:16
12/14/17
12/14
15:16
12/14/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

15:12
12/14/17
12/14
15:12
12/14/17
15:12
Periodicals
Speaker Ryan says not leaving Congress anytime soon, CBS News reports »

Following a media report…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.05

-0.705 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$2.93

-0.095 (-3.15%)

15:10
12/14/17
12/14
15:10
12/14/17
15:10
Options
Bulls and bears in JC Penney Thursday »

Bulls and bears in JC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

, CMCSK

Comcast

15:06
12/14/17
12/14
15:06
12/14/17
15:06
Periodicals
Comcast offered more for Fox assets, but Fox preffered Disney deal, CNBC says »

Sources tell CNBC's…

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

COST

Costco

$188.28

-0.02 (-0.01%)

15:04
12/14/17
12/14
15:04
12/14/17
15:04
Options
Costco options imply 5.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VRX

Valeant

$19.22

-2.83 (-12.83%)

15:03
12/14/17
12/14
15:03
12/14/17
15:03
Technical Analysis
Technical View: Valeant near session lows, levels to watch »

The shares are bouncing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 27

    Dec

  • 18

    Jun

CI

Cigna

$204.17

-3.75 (-1.80%)

15:02
12/14/17
12/14
15:02
12/14/17
15:02
Hot Stocks
Cigna announces acquisition of digital health plan platform Brighter »

Cigna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/14/17
12/14
15:00
12/14/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ORCL

Oracle

$50.25

0.195 (0.39%)

14:49
12/14/17
12/14
14:49
12/14/17
14:49
Options
Oracle options imply 7.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DIS

Disney

$111.04

3.43 (3.19%)

, FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

14:44
12/14/17
12/14
14:44
12/14/17
14:44
Recommendations
Disney, 21st Century Fox analyst commentary  »

RBC Capital sees Disney,…

DIS

Disney

$111.04

3.43 (3.19%)

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

PGR

Progressive

$55.20

-0.66 (-1.18%)

14:40
12/14/17
12/14
14:40
12/14/17
14:40
Options
Notable put buying in Progressive »

Notable put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$19.42

-2.6299 (-11.93%)

14:38
12/14/17
12/14
14:38
12/14/17
14:38
Hot Stocks
Valeant slips after JPMorgan says sell on stretched valuation, high expectations »

Shares of Valeant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 27

    Dec

  • 18

    Jun

LNCE

Snyder's-Lance

$39.41

0.16 (0.41%)

14:35
12/14/17
12/14
14:35
12/14/17
14:35
Hot Stocks
Breaking Hot Stocks news story on Snyder's-Lance »

Snyder's & Lance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.